Abstract:Since the National Cancer Act established the Cancer Centers Program in 1971, NCI-designated cancer centers (NCI-CCs) throughout the country have been mandated to translate state-of-the-art cancer research to communities and enhance clinical care for patients within their catchment areas, including minority and underrepresented populations. Precision oncology, which leverages genetics to optimize personalized treatment plans for patients, has promising potential to address cancer health disparities. In this era of targeted personalized care, though genetics has been incorporated into cancer centers, it is unknown how these innovations are being communicated to the public and communities served. There is particularly limited knowledge surrounding how cancer centers may integrate patient reported experiences with genomics into fulfilling their overall mission and reducing cancer health disparities. The objective of this study was to evaluate how cancer centers are publicly sharing information related to their work in understanding and assessing patient experiences with the use of genetics to guide cancer care. For all NCI-CCs involved in clinical care (n=65), we conducted a review of publicly available and published information, using each cancer center website as a point of origin. While almost all the NCI-CCs discuss providing personalized care and perform genetic testing, we found that the majority (51%) indicate that they assess patient-reported outcomes with genomic medicine, such as symptom monitoring during clinical trials. Fewer (38%) indicated having at least one study or that they assess patient experiences and perspectives with genomic medicine that extended to broader measures, like hereditary testing or pharmacogenomic testing to guide treatment. Forty-five percent of NCI-CCs indicate that any pharmacogenomic testing is performed through standard care, research studies, or otherwise. Finally, about 1 in 3 (35%) indicate that they have departmental resources dedicated to monitoring patient experience at their institutions. Some centers described having an established infrastructure dedicated to measuring and incorporating patient reported experiences into programmatic activities, such as offices and annual events dedicated to patient experience. These centers reflecting a built-in infrastructure were 8 to 12% more likely to publicly communicate and describe targeted activities to assess patient reported outcomes and experiences with genomic medicine and/or provide genetic testing. The use of genomics in research and clinical care continues to expand, yet its impact on the minority and underrepresented communities that cancer centers serve remains uncharacterized. Comprehensive understanding of patient reported experience with genomic medicine is lagging and serves as a key opportunity to potentially address cancer health disparities. As leaders in cancer care, NCI-CCs have the opportunity to enhance communication with communities surrounding genomics and improve the patient-centered care they provide. Citation Format: Amanda S. Andriessen, Loren Saulsberry. Incorporating the Patient Voice: An Evaluation of NCI-Designated Cancer Centers and Patient Reported Experiences with Genomic Medicine [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl) nr B023.

Reporting tumor genomic test results to SEER registries via linkages

History of the Surveillance, Epidemiology, and End Results (SEER) Program

Virtual Pooled Registry-Cancer Linkage System: an improved method for ascertaining cancer diagnoses

Towards precision medicine: discovering novel gynecological cancer biomarkers and pathways using linked data

From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards

Time-varying associations of patient and tumor characteristics with cancer survival: an analysis of SEER data across 14 cancer sites, 2004–2017

Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing: A Prospective Interventional Study

Abstract 5028: Integration of molecular data into cancer patient database

Identifying Associations between Somatic Mutations and Clinicopathologic Findings in Lung Cancer Pathology Reports

Racial and socioeconomic disparities in NSCLC molecular diagnostics uptake

Sociodemographic and Clinical Characteristics Associated with Genetic Testing among Cancer Survivors: Evidence from Three Cancer Registries

Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors

Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy

Population-Based Data Linkage Describing Patterns of Cancer Clinical Trial Enrollment Among Children and Adolescents

Surveillance, epidemiology, and end results (SEER) and SEER-medicare databases: use in clinical research for improving colorectal cancer outcomes

Real-world lessons: combining cancer registry and retail pharmacy data for oral cancer drugs

Abstract B023: Incorporating the Patient Voice: An Evaluation of NCI-Designated Cancer Centers and Patient Reported Experiences with Genomic Medicine

Electronic Medical Record–Based Nudge Intervention to Increase Comprehensive Molecular Genotyping in Patients With Metastatic Non–Small Cell Lung Cancer: Results From a Prospective Clinical Trial

Stratification of patients by tumor type using molecular profiling in real-world data.

Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme